Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

Phase 2positiveEP-104GIPositive

AI Analysis

Summary

Eupraxia Pharmaceuticals announced positive interim data from its Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis patients, including new analysis of odynophagia (painful swallowing) outcomes using the Dysphagia Symptom Questionnaire.

Clinical Trial Data

Phase

1b/2a

Outcome Details

Positive results from RESOLVE study analysis showing effect of EP-104GI on symptom severity including odynophagia (painful swallowing) in EoE patients

Importance:6/10

Sentiment:

0.70

clinical_trialphase_1b_2aeosinophilic_esophagitissymptom_responsepatient_reported_outcome

Related Companies

$EPRX

Read the original article

Published by GlobeNewswire Pharma on August 13, 2026 12:00 PM

Read Original